文献速递骨肿瘤创伤骨科

四肢骨巨细胞瘤合并病理性骨折局部复发的预后因素

Prognostic factors for local recurrence in extremity-located giant cell tumours of bone with pathological fracture.
PubMed 文献 · Bone Joint J · 2018-01-01

回顾性分析1995至2016年单中心107例四肢骨巨细胞瘤合并病理性骨折患者,局部复发28例(25%)。未用德诺苏单抗的Campanacci 3期肿瘤整块切除局部复发(13%)低于刮除(39%);Campanacci 2期刮除与整块切除复发率相似(21%与24%)。德诺苏单抗后刮除者全部复发,其获益仍不明确。

要点

  • 未用德诺苏单抗的Campanacci 3期肿瘤整块切除局部复发13%,低于刮除的39%。
  • Campanacci 2期肿瘤刮除与整块切除局部复发率相似(21%与24%)。
  • 德诺苏单抗后行病灶内刮除者全部出现局部复发。

核心结论

  • 在未接受德诺苏单抗治疗的骨巨细胞瘤合并病理性骨折患者中,Campanacci 3期肿瘤行整块切除的局部复发风险低于病灶内刮除。
  • Campanacci 2期肿瘤行病灶内刮除或整块切除的局部复发风险相似。
  • 德诺苏单抗后行病灶内刮除的获益仍不明确。

研究设计与样本

  • 回顾性研究纳入了1995年至2016年在皇家骨科医院(Royal Orthopaedic Hospital,英国伯明翰)本机构治疗的107例骨巨细胞瘤合并病理性骨折患者。
  • 其中女性57例(53%),男性50例(47%);诊断时平均年龄33岁(范围14至86岁)。
  • 先进行单变量分析,随后进行多变量分析,基于治疗和临床特征识别危险因素。

主要发现

  • 初始手术治疗为病灶内刮除伴或不伴辅助治疗55例(51%),整块切除伴或不伴重建45例(42%),新辅助德诺苏单抗后切除3例(3%)或刮除4例(4%)。
  • 局部复发28例(25%)。
  • 骨折后超过6周手术在任何组中均未影响复发风险。
  • 在未接受德诺苏单抗治疗的Campanacci 3期肿瘤中,整块切除的局部复发率为13%,低于病灶内刮除的39%。
  • 在Campanacci 2期肿瘤中,病灶内刮除与整块切除的复发率相似(分别为21%与24%)。

关键数值与推荐

  • 单变量分析后,手术干预类型、肿瘤位置和德诺苏单抗的使用是预测局部复发的独立因素。
  • 与整块切除相比,病灶内刮除后需要再次手术的频率高33%(平均手术次数1.59次,范围0至5次 vs 1.06次,范围0至3次)。
  • 所有接受德诺苏单抗后行病灶内刮除的患者均出现局部复发。

临床怎么用

  • 对于未接受德诺苏单抗治疗的Campanacci 3期骨巨细胞瘤合并病理性骨折患者,整块切除的局部复发风险低于病灶内刮除。
  • 对于Campanacci 2期肿瘤,病灶内刮除或整块切除在局部复发风险方面是相似的选择。
  • 德诺苏单抗后行病灶内刮除的获益仍不明确。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aim of this paper was to investigate the prognostic factors for local recurrence in patients with pathological fracture through giant cell tumours of bone (GCTB). PATIENTS AND METHODS: A total of 107 patients presenting with fractures through GCTB treated at our institution (Royal Orthopaedic Hospital, Birmingham, United Kingdom) between 1995 and 2016 were retrospectively studied. Of these patients, 57 were female (53%) and 50 were male (47%).The mean age at diagnosis was 33 years (14 to 86). A univariate analysis was performed, followed by multivariate analysis to identify risk factors based on the treatment and clinical characteristics. RESULTS: The initial surgical treatment was curettage with or without adjuvants in 55 patients (51%), en bloc resection with or without reconstruction in 45 patients (42%), and neoadjuvant denosumab, followed by resection (n = 3, 3%) or curettage (n = 4, 4%). The choice of treatment depended on tumour location, Campanacci tumour staging, intra-articular involvement, and fracture displacement. Neoadjuvant denosumab was used only in fractures through Campanacci stage 3 tumours. Local recurrence occurred in 28 patients (25%). Surgery more than six weeks after the fracture did not affect the risk of recurrence in any of the groups. In Campanacci stage 3 tumours not treated with denosumab, en bloc resection had lower local recurrences (13%), compared with curettage (39%). In tumours classified as Campanacci 2, intralesional curettage and en bloc resections had similar recurrence rates (21% and 24%, respectively). After univariate analysis, the type of surgical intervention, location, and the use of denosumab were independent factors predicting local recurrence. Further surgery was required 33% more often after intralesional curettage in comparison with resections (mean 1.59, 0 to 5 vs 1.06, 0 to 3 operations). All patients treated with denosumab followed by intralesional curettage developed local recurrence. CONCLUSION: In patients with pathological fractures through GCTB not treated with denosumab, en bloc resection offers lower risks of local recurrence in tumours classified as Campanacci stage 3. Curettage or resections are both similar options in terms of the risk of local recurrence for tumours classified as Campanacci stage 2. The benefits of denosumab followed by intralesional curettage in these patients still remains unclear.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Medellin MR, Fujiwara T, Tillman RM, et al. Prognostic factors for local recurrence in extremity-located giant cell tumours of bone with pathological fracture. Bone Joint J. 2018. PMID: 30499317. doi:10.1302/0301-620X.100B12.BJJ-2018-0189.R2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。